Quick verdict
Embla is the better pick for most patients on overall scoring. Embla is the closest thing the US market has to a Noom-meets-Calibrate hybrid that actually leans into the medication. Heavy behavioral coaching, branded-first prescribing, structured 12-month curriculum. Best for buyers who want the program to do half the work.
That said, Found wins on specific dimensions. Found has the broadest medication catalog of any program here, including off-label tirzepatide and orforglipron access through their Foundayo program. The 6-month non-refundable subscription is the catch.
Side-by-side
| Found | Embla | |
|---|---|---|
| Starts from | $99/mo (+ med separate) | $249/mo (+ med separate) |
| Lock-in | 6-month lock-in | 12-month commitment |
| Time to prescription | 5 days | 7 days |
| Consultation type | Asynchronous | Synchronous |
| Affiliate network | Impact | Impact |
Score by dimension
Five dimensions, ten points each. The winner of each dimension is highlighted.
| Found | Embla | |
|---|---|---|
| Pricing transparency | 6/10 | 6/10 |
| Cancellation terms | 3/10 | 7/10 |
| Onboarding experience | 8/10 | 6/10 |
| Medication options | 9/10 | 7/10 |
| Member outcomes | 5/10 | 8/10 |
When to choose Found
Patients whose obesity medicine clinician has flagged a non-standard medication path (multiple drug classes, off-label combinations, or 503A-compounded options that other programs have exited).
When to choose Embla
Patients who tried meds-only and bounced, and want a structured behavior program alongside GLP-1.
FAQ
Is Found cheaper than Embla?
Can I switch from Found to Embla mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart →